Antihistamine after a heart attack
Part of Heart & circulation clinical trials.
This trial tests whether taking an antihistamine medicine called fexofenadine hydrochloride can help people recover better after a heart attack. It is a randomized study, so some participants will receive the medicine and others will receive a placebo (a pill with no active ingredients).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You had a type of heart attack called STEMI, confirmed by chest pain, blood tests, and ECG changes.
- You had emergency heart procedure (coronary angiography) to open a blocked artery.
- An ultrasound of the heart showed your heart pump function is reduced (LVEF at or below 50%).
- You have not had a previous heart attack, heart bypass surgery, or long-term use of fexofenadine or similar allergy medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether dexmedetomidine can protect the heart in people who are having a specific type of heart attack (anterior STEMI) when treated within 6 hours of symptom start. You may be considered if your diagnosis and vital signs fit the study safety rules, and if you can take part in follow-up.
This study tests whether giving a medication called adenosine before emergency heart catheterization (a tube procedure to open blocked arteries) helps patients having a heart attack. Adenosine may protect heart tissue and improve outcomes.
This trial tests if the allergy medicine fexofenadine can improve recovery after a heart attack. You may qualify if you had a specific type of heart attack (STEMI) within the last week.
This trial tests whether combining antioxidant supplements with standard heart attack care can reduce heart muscle damage. It may help people who are getting emergency treatment for their first heart attack.
This study tests a new drug called ziltivekimab to see if it helps people who have recently had a heart attack. The drug is given as an injection and compared to a placebo (a shot with no active medicine).
This Phase 2 trial tests whether blocking serotonin receptors can help after a first heart attack that has caused a specific type of leaking mitral valve problem. It aims to see if the treatment improves heart function and heart-valve measurements while keeping patients safe.
Hear when a new ST-segment Elevation Myocardial Infarction (STEMI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.